ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Cymbalta (duloxetine) by Year
Cymbalta (duloxetine) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly Cymbalta (duloxetine): -51.0% in FY2022, down 27.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2022
-51.0%
Period ended Dec 31, 2022
Change on a year earlier
-27.0 pts
-24.0% in FY2021
History
6 years
Since FY2017
Sources
6
Documents cited below
Where the FY2022 figure comes from
“|| Cymbalta | 33.7 | 249.6 | 283.3 | 581.5 | (51)”
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cymbalta (duloxetine) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | -51.0% | -27.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | -24.0% | -30.0 pts | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 6.0% | +12.0 pts | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | -6.0% | +13.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | -19.0% | -10.0 pts | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | -9.0% | – | Form 10-K FY2017 (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cymbalta (duloxetine) (%), annual FY2017–FY2022 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-cymbalta-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.